Live Breaking News & Updates on ராபர்ட் காட்டு

Stay updated with breaking news from ராபர்ட் காட்டு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting


Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
Share Article
Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma
New York, NY (PRWEB)
April 05, 2021
Dracen Pharmaceuticals, Inc., announced today that three posters profiling its clinical stage glutamine antagonist, DRP-104 (sirpiglenastat), will be presented Saturday, April 10 - Monday, June 21 during the American Association for Cancer Research (AACR) Virtual Annual Meeting.
“As our lead asset DRP-104 (sirpiglenastat) advances in phase I clinical development, our preclinical data continues to confirm its promising profile both as a single agent and in combination therapy,” said Robert Wild, Ph.D., ....

United States , New York , San Diego , Czech Republic , Robert Wild , American Association For Cancer Research , Institute Of Organic Chemistry , Osage University Partners , Dracen Pharmaceuticals , Dracen Pharmaceuticals Inc , American Association , Cancer Research , Virtual Annual , E Poster Session , Abstract Number , Metabolic Pathways , Deerfield Management , Norganic Chemistry , Press Release , ஒன்றுபட்டது மாநிலங்களில் , புதியது யார்க் , சான் டியாகோ , செக் குடியரசு , ராபர்ட் காட்டு , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , நிறுவனம் ஆஃப் ஆர்க்யாநிக் வேதியியல் ,